deucravacitinib抑制TYK2在活动性SLE中的药效学分析:2期PAISLEY试验结果
该研究基于2期PAISLEY SLE试验,对363例活动性SLE患者及至多60例健康志愿者样本进行药效学分析,评估deucravacitinib(选择性口服TYK2抑制剂)对免疫相关通路和血清生物标志物的影响。结果显示deucravacitinib快速且持续降低干扰素水平及干扰素应答基因、干扰素诱导蛋白、B细胞通路标志物和血清生物标志物,并升高补体C3和C4,支持其继续在3期试验中评估。
要点
- deucravacitinib快速持续降低SLE患者干扰素水平和干扰素应答基因表达。
- deucravacitinib降低B细胞通路标志物和血清生物标志物,升高补体C3和C4。
- deucravacitinib降低干扰素高和低亚组的干扰素特征评分,以及干扰素高亚组的抗dsDNA抗体滴度。
核心结论
- deucravacitinib在SLE患者中抑制干扰素和B细胞通路生物标志物,支持其继续在3期试验中评估。
研究设计与样本
- 2期PAISLEY SLE试验的药效学分析,纳入363例SLE患者和至多60例人口学匹配的健康志愿者样本。
- 采用化学连接依赖探针扩增、免疫分析和临床实验室检测分析全血转录本、血清蛋白、血细胞亚群和抗体谱。
- 化学连接依赖探针扩增在4项独立研究的全血样本中测量51个免疫系统相关基因。
- 所有分析均为描述性。
主要发现
- 筛选时,SLE患者与健康志愿者相比有42个基因和75个蛋白差异表达。
- deucravacitinib治疗快速且持续降低干扰素水平、干扰素应答基因表达、干扰素诱导蛋白、B细胞通路标志物和血清生物标志物。
- deucravacitinib治疗升高补体C3和C4表达,动力学与安慰剂相似。
- deucravacitinib降低干扰素高和低亚组的干扰素特征评分。
- deucravacitinib降低干扰素高亚组的抗双链DNA抗体滴度。
关键数值与推荐
- 筛选时SLE患者与健康志愿者间有42个基因和75个蛋白差异表达。
- 化学连接依赖探针扩增测量51个免疫系统相关基因。
临床怎么用
- deucravacitinib通过抑制干扰素和B细胞通路生物标志物发挥药效学作用,支持在3期试验中进一步评估其治疗SLE的疗效。
局限性
- 所有分析均为描述性,未报告统计推断或P值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this paper is to evaluate pharmacodynamic changes in immune-related pathways and serological biomarkers mediated by tyrosine kinase 2 (TYK2) inhibition in patients with systemic lupus erythematosus (SLE) treated with deucravacitinib, an oral, selective TYK2 inhibitor, in the phase 2 PAISLEY SLE trial. METHODS: Whole-blood transcripts, serum proteins, blood cell subsets, and antibody profiles were analysed via chemical ligation-dependent probe amplification assays, immunoassays, and clinical laboratory assays in 363 patients with SLE from the PAISLEY SLE trial and up to 60 commercially sourced healthy volunteer samples matched demographically to patients. Chemical ligation-dependent probe amplification was used to measure 51 immune system-related genes in whole-blood samples collected in 4 independent studies. All analyses were descriptive. RESULTS: At screening, 42 genes and 75 proteins were differentially expressed in patients with SLE vs healthy volunteers. Deucravacitinib treatment resulted in rapid and sustained reductions in interferon (IFN) levels and expression of IFN-responsive genes, IFN-inducible proteins, B-cell pathway markers, and serological biomarkers and increases in complement 3 and 4 expression with similar kinetics vs placebo. Deucravacitinib treatment reduced an IFN signature score in IFN-high and IFN-low subgroups and anti-double-stranded DNA antibody titres in the IFN-high subgroup. CONCLUSIONS: Deucravacitinib demonstrated suppression of IFN and B-cell pathway biomarkers in patients with SLE, supporting its continued evaluation in ongoing phase 3 trials (Program for Evaluation of TYK2 [POETYK] SLE-1 [NCT05617677] and POETYK SLE-2 [NCT05620407]).
引用
- Kahlenberg JM, Wu C, Vital E, et al. Pharmacodynamic analysis of TYK2 inhibition by deucravacitinib: results from the phase 2 PAISLEY SLE trial in patients with active systemic lupus erythematosus. Ann Rheum Dis. 2026. PMID: 42660739. doi:10.1016/j.ard.2026.07.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。